Allergy Therapeutics PLC Stock
Price
Target price
€0.13
€0.13
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Allergy Therapeutics PLC in the next few years
Pros
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Allergy Therapeutics PLC vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Allergy Therapeutics PLC | - | 0.806% | 7.759% | 67.785% | 6.838% | 163.158% | -50.000% |
| Beximco Pharmaceuticals Ltd. GDR | 0.000% | 0.000% | 0.980% | 19.767% | 14.955% | 7.292% | -47.449% |
| Eledon Pharmaceuticals Inc. | -0.860% | 4.545% | 39.394% | -29.448% | 79.688% | 19.171% | -79.825% |
| SELLAS Life Sciences Group Inc | 7.560% | -1.677% | 55.298% | 345.817% | 65.432% | 258.289% | -49.439% |
News
2 No-Brainer Dividend Stocks to Buy Right Now
Blue chip dividend stocks are usually stable long-term investments, but they lost their luster in 2022 and 2023 as rising interest rates made CDs and T-bills more attractive. However, the Federal
AT&T's Earnings Glow-Up Can't Hide These Red Flags
On paper, a company that just turned 141 years old and increased its net income from $10.7 billion in 2024 to $21.9 billion in 2025 may not seem like a likely sell candidate.
That argument
AT&T's Secret Weapon for 2026: Why Fiber Could Drive Double-Digit EPS Growth
Telecom powerhouse AT&T (NYSE: T) is certainly a respectable company and a great dividend payer. But is it a growth stock? Hardly.
Except, for the foreseeable future, it's going to be putting up